SCG2

Summary

SCG2 (secretogranin II, HGNC:10575) is a protein-coding gene on chromosome 2q36.1, encoding Secretogranin-2 (P13521). Neuroendocrine protein of the granin family that regulates the biogenesis of secretory granules.

The protein encoded by this gene is a member of the chromogranin/secretogranin family of neuroendocrine secretory proteins. Studies in rodents suggest that the full-length protein, secretogranin II, is involved in the packaging or sorting of peptide hormones and neuropeptides into secretory vesicles. The full-length protein is cleaved to produce the active peptide secretoneurin, which exerts chemotaxic effects on specific cell types, and EM66, whose function is unknown.

Source: NCBI Gene 7857 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 75 total
• MANE Select transcript: NM_003469

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10575
Approved symbol	SCG2
Name	secretogranin II
Location	2q36.1
Locus type	gene with protein product
Status	Approved
Aliases	CHGC, SgII, SN
Ensembl gene	ENSG00000171951
Ensembl biotype	protein_coding
OMIM	118930
Entrez	7857

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000305409, ENST00000421386, ENST00000433889

RefSeq mRNA: 1 — MANE Select: NM_003469 NM_003469

CCDS: CCDS2457

Canonical transcript exons

ENST00000305409 — 2 exons

Exon	Start	End
ENSE00001147047	223596940	223599296
ENSE00001741793	223602285	223602361

Expression profiles

Bgee: expression breadth ubiquitous, 216 present calls, max score 99.38.

FANTOM5 (CAGE): breadth broad, TPM avg 25.4013 / max 3624.6986, expressed in 644 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
34159	22.5001	633
34160	2.8201	242
34161	0.0602	16
34163	0.0166	5
34162	0.0043	1

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
type B pancreatic cell	CL:0000169	99.38	gold quality
islet of Langerhans	UBERON:0000006	99.24	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.69	gold quality
superior vestibular nucleus	UBERON:0007227	98.43	gold quality
pituitary gland	UBERON:0000007	98.30	gold quality
hypothalamus	UBERON:0001898	98.28	gold quality
nucleus accumbens	UBERON:0001882	98.08	gold quality
substantia nigra pars compacta	UBERON:0001965	97.62	gold quality
middle temporal gyrus	UBERON:0002771	97.54	gold quality
adenohypophysis	UBERON:0002196	97.51	gold quality
substantia nigra pars reticulata	UBERON:0001966	97.49	gold quality
prefrontal cortex	UBERON:0000451	97.26	gold quality
orbitofrontal cortex	UBERON:0004167	97.20	gold quality
Brodmann (1909) area 10	UBERON:0013541	96.69	gold quality
endothelial cell	CL:0000115	96.62	gold quality
pons	UBERON:0000988	96.52	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	96.49	gold quality
ventral tegmental area	UBERON:0002691	96.46	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.19	gold quality
caudate nucleus	UBERON:0001873	96.14	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.04	gold quality
frontal pole	UBERON:0002795	95.72	gold quality
putamen	UBERON:0001874	95.70	gold quality
cingulate cortex	UBERON:0003027	95.55	gold quality
anterior cingulate cortex	UBERON:0009835	95.48	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.30	gold quality
frontal cortex	UBERON:0001870	95.09	gold quality
frontal lobe	UBERON:0016525	95.09	gold quality
midbrain	UBERON:0001891	95.01	gold quality
Brodmann (1909) area 46	UBERON:0006483	95.00	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 14.

Experiment	Marker?	Max mean expression
E-MTAB-9154	yes	5400.56
E-CURD-114	yes	5112.32
E-HCAD-31	yes	4463.90
E-GEOD-137537	yes	2758.15
E-GEOD-93593	yes	2012.51
E-HCAD-25	yes	36.62
E-GEOD-81547	yes	30.31
E-MTAB-5061	yes	27.42
E-GEOD-83139	yes	12.73
E-ENAD-27	yes	9.88
E-GEOD-125970	yes	8.26
E-GEOD-84465	yes	6.73
E-HCAD-10	yes	5.18
E-GEOD-81608	no	7.97
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ATF4, CREB1, REST, TBP

miRNA regulators (miRDB)

81 targeting SCG2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-548AZ-3P	99.82	70.56	3549

Literature-anchored findings (GeneRIF, showing 29)

• Transendothelial migration of leukocytes and signalling mechanisms in response to the neuropeptide secretoneurin. (PMID:11853870)
• secretogranin II-derived peptide EM66 generated in human tumoral chromaffin tissue; significant difference in EM66 concentrations between benign and malignant pheochromocytomas (PMID:12788858)
• the high concentration of secretoneurin in the aqueous humor indicates a significant role of this peptide (PMID:15572199)
• a variant of Secretogranin II has a role in regulation by PHOX2 transcription factors and in hypertension (PMID:17584765)
• Results suggest that secretogranin II represents a key AP-1-regulated protein that counteracts nitric oxide toxicity and mediates neuronal differentiation of neuroblastoma cells. (PMID:18239671)
• Increased concentrations of SgII, especially the N-terminal part of secretoneurin could be measured in plasma from patients with endocrine pancreatic tumours. (PMID:18448176)
• Suppression of Pdcd4 resulted in an increased release of CgA and Sg II and was accompanied by an up-regulation of intracellular PC1. (PMID:18549351)
• semiquantitative immunocytochemistry for secretogranin II in amyotrophic lateral sclerosis. (PMID:18721831)
• More SgII immunoreactive cells were observed in phaeochromocytomas. (PMID:20550951)
• This short review deals with investigations in neuroendocrine tumors (NETs) with antibodies against defined epitopes of chromogranins (Cgs) A and B and secretogranins (Sgs) II and III. (PMID:21046454)
• Manserin may serve as a marker of prostate cancer progression. (PMID:21803620)
• Data describe the gene expression and protein production of SgII in normal adrenal glands and pheochromocytomas with the goal to examine the molecular mechanisms leading to the marked variations in the expression of EM66 in tumoral chromaffin tissue. (PMID:22217803)
• Circulating Levels of SgII are Increased in Patients with chronic, stable heart failure. (PMID:22655045)
• In vivo secretoneurin improves left ventricular function, inhibits remodeling, and reduces scar formation; in the infarct border zone, secretoneurin induces coronary angiogenesis. (PMID:23081990)
• CgA, CgB, and secretoneurin are detectable in feces, and collagenous colitis patients express higher values than patients with inflammatory bowel disease and controls. In treatment, fecal secretoneurin decreased to control levels in collagenous colitis. (PMID:23423580)
• Topical secretoneurin gene therapy accelerates diabetic wound healing by interaction between heparan-sulfate proteoglycans and basic FGF. (PMID:23918206)
• SN induces MUC5AC hypersecretion in a dose- and time-dependent manner; moreover, the MUC5AC over synthesis induced by SN is strongly associated with the enhanced binding of EGF to NRP1 (PMID:24556756)
• present data show that SgII is highly expressed in advanced prostate cancer and may contribute to the neuroendocrine differentiation by promoting the formation of secretory granules and the proliferation of PCa cells. (PMID:25307750)
• Differential Reovirus-Specific and Herpesvirus-Specific Activator Protein 1 Activation of Secretogranin II Leads to Altered Virus Secretion. (PMID:26378181)
• serum levels of CgA, CgB, and SgII were determined in Parkinson’s disease patients and assessed their association with disease severity. (PMID:30887724)
• Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia-inducible factor-1alpha in colorectal cancer. (PMID:34160138)
• Nanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder. (PMID:34815513)
• AGTR1, PLTP, and SCG2 associated with immune genes and immune cell infiltration in calcific aortic valve stenosis: analysis from integrated bioinformatics and machine learning. (PMID:35341274)
• SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer. (PMID:35844556)
• Investigation of secretoneurin as a potential biomarker of brain injury in very preterm infants: A pilot study. (PMID:37023080)
• Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-kappaB pathways. (PMID:37848672)
• [High expression of secretogranin II increases oxaliplatin resistance of colorectal cancer cells]. (PMID:37933640)
• Circulating secretoneurin level reflects angiographic coronary collateralization in stable angina patients with chronic total occlusion. (PMID:38184555)
• Prognostic value of plasma secretoneurin concentration in patients with heart failure with reduced ejection fraction in one-year follow-up. (PMID:38261566)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	scg2b	ENSDARG00000038574
mus_musculus	Scg2	ENSMUSG00000050711
rattus_norvegicus	Scg2	ENSRNOG00000015055

Protein

Protein identifiers

Secretogranin-2 — P13521 (reviewed: P13521)

Alternative names: Chromogranin-C, Secretogranin II

All UniProt accessions (3): P13521, C9JDT0, C9JQI2

UniProt curated annotations — full annotation on UniProt →

Function. Neuroendocrine protein of the granin family that regulates the biogenesis of secretory granules.

Subunit / interactions. Interacts with Secretogranin III/SCG3.

Subcellular location. Secreted.

Post-translational modifications. O-glycosylated.

Miscellaneous. Binds calcium with a low-affinity.

Similarity. Belongs to the chromogranin/secretogranin protein family.

RefSeq proteins (1): NP_003460* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001990	Granin	Family
IPR018054	Chromogranin_CS	Conserved_site
IPR038858	ScgII	Family

Pfam: PF01271

UniProt features (25 total): modified residue 7, sequence variant 6, region of interest 4, compositionally biased region 2, peptide 2, signal peptide 1, propeptide 1, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P13521-F1	58.07	0.12

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 151, 174, 268, 432, 532, 555, 556

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
R-HSA-8957275	Post-translational protein phosphorylation
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 268 (showing top): ATF_B, GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_CELL_PROLIFERATION, MODULE_92, GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_CELL_CHEMOTAXIS, GOBP_INFLAMMATORY_RESPONSE, GOCC_SECRETORY_GRANULE, GOBP_INDUCTION_OF_POSITIVE_CHEMOTAXIS, GOBP_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, CREBP1_Q2, GOBP_REGULATION_OF_POSITIVE_CHEMOTAXIS, GOBP_LEUKOCYTE_CHEMOTAXIS, CREB_Q4, MODULE_66, WEI_MYCN_TARGETS_WITH_E_BOX

GO Biological Process (13): MAPK cascade (GO:0000165), angiogenesis (GO:0001525), negative regulation of endothelial cell proliferation (GO:0001937), positive regulation of endothelial cell proliferation (GO:0001938), inflammatory response (GO:0006954), protein secretion (GO:0009306), intracellular signal transduction (GO:0035556), endothelial cell migration (GO:0043542), eosinophil chemotaxis (GO:0048245), positive chemotaxis (GO:0050918), induction of positive chemotaxis (GO:0050930), negative regulation of endothelial cell apoptotic process (GO:2000352), negative regulation of extrinsic apoptotic signaling pathway (GO:2001237)

GO Molecular Function (3): cytokine activity (GO:0005125), chemoattractant activity (GO:0042056), protein binding (GO:0005515)

GO Cellular Component (6): obsolete extracellular space (GO:0005615), endoplasmic reticulum lumen (GO:0005788), secretory granule (GO:0030141), neuronal dense core vesicle (GO:0098992), extracellular region (GO:0005576), dense core granule (GO:0031045)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Metabolism of proteins	2
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
endothelial cell proliferation	2
regulation of endothelial cell proliferation	2
receptor ligand activity	2
intracellular signaling cassette	1
blood vessel morphogenesis	1
anatomical structure formation involved in morphogenesis	1
negative regulation of epithelial cell proliferation	1
positive regulation of epithelial cell proliferation	1
defense response	1
protein transport	1
secretion by cell	1
establishment of protein localization to extracellular region	1
protein localization to extracellular region	1
intracellular anatomical structure	1
signal transduction	1
cell migration	1
granulocyte chemotaxis	1
eosinophil migration	1
chemotaxis	1
positive regulation of positive chemotaxis	1
negative regulation of apoptotic process	1
endothelial cell apoptotic process	1
regulation of endothelial cell apoptotic process	1
extrinsic apoptotic signaling pathway	1
negative regulation of apoptotic signaling pathway	1
regulation of extrinsic apoptotic signaling pathway	1
positive chemotaxis	1
binding	1
endoplasmic reticulum	1
intracellular organelle lumen	1
endomembrane system	1
secretory vesicle	1
dense core granule	1
cellular anatomical structure	1
secretory granule	1

Protein interactions and networks

STRING

1092 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SCG2	CHGB	P05060	972
SCG2	CHGA	P10645	939
SCG2	SCG3	Q8WXD2	908
SCG2	SCG5	P01164	826
SCG2	CPE	P16870	751
SCG2	PCSK1N	Q9UHG2	681
SCG2	VGF	O15240	674
SCG2	TAC1	P20366	623
SCG2	NPY	P01303	557
SCG2	PENK	P01210	545
SCG2	SYP	P08247	544
SCG2	TAC3	Q9UHF0	529
SCG2	STAT3	P40763	511
SCG2	BMP8A	Q7Z5Y6	497
SCG2	ATP10A	O60312	490
SCG2	BMP8B	P34820	490

IntAct

21 interactions, top by confidence:

A	B	Type	Score
SCG2	UBQLN1	psi-mi:“MI:0915”(physical association)	0.670
SCG2	ATRIP	psi-mi:“MI:0915”(physical association)	0.560
SCG3	SCG2	psi-mi:“MI:0915”(physical association)	0.510
SCG2	PIK3R1	psi-mi:“MI:0915”(physical association)	0.400
SCG2	PLEC	psi-mi:“MI:0915”(physical association)	0.400
SCG2	DCAF6	psi-mi:“MI:0915”(physical association)	0.400
TUBB4B	SCG2	psi-mi:“MI:0915”(physical association)	0.370
COPS6	DDX3X	psi-mi:“MI:0914”(association)	0.350
VCP	FAM171A2	psi-mi:“MI:0914”(association)	0.350
UBQLN1	SCG2	psi-mi:“MI:0915”(physical association)	0.000
TNF	SCG2	psi-mi:“MI:0915”(physical association)	0.000
SCHIP1	SCG2	psi-mi:“MI:0915”(physical association)	0.000
NRIP1	SCG2	psi-mi:“MI:0915”(physical association)	0.000
UBQLN4	SCG2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): ATRIP (Two-hybrid), SCG2 (Two-hybrid), SCG2 (Affinity Capture-MS), SCG2 (Two-hybrid), PLEC (Proximity Label-MS), SCG2 (Affinity Capture-RNA), DCAF6 (Affinity Capture-MS), SCG2 (Affinity Capture-MS), SCG2 (PCA), SCG2 (Affinity Capture-MS), SCG2 (Two-hybrid), HSP90AA1 (Cross-Linking-MS (XL-MS)), HSP90AB1 (Cross-Linking-MS (XL-MS)), TRMT1 (Cross-Linking-MS (XL-MS)), SCG2 (Affinity Capture-MS)

ESM2 similar proteins: A0JMK6, A5A6J6, B9WZ56, C0HKY1, C0HM54, E1ZXU8, O12956, O35314, O35417, O70176, P01165, P01282, P01362, P05060, P05408, P06300, P06308, P10362, P12285, P12961, P13521, P13589, P16014, P16613, P17685, P17686, P18509, P18844, P20616, P23389, P27682, P30945, P41534, P41535, P41585, P45644, P48143, P48144, P81401, P85799

Diamond homologs: P10362, P13521, P20616, P30945, Q03517, Q4R5E9, Q5FZP5, Q5R4M6, A0JMK6, C0HM54

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

75 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	71
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

452 predictions. Top by Δscore:

Variant	Effect	Δscore
2:223602279:CCTTA:C	donor_loss	1.0000
2:223602280:CTTA:C	donor_loss	1.0000
2:223602281:TTA:T	donor_loss	1.0000
2:223602282:TA:T	donor_loss	1.0000
2:223602283:A:AC	donor_gain	1.0000
2:223602284:C:CC	donor_gain	1.0000
2:223602284:CCT:C	donor_gain	1.0000
2:223599293:TTTC:T	acceptor_gain	0.9900
2:223599296:CC:C	acceptor_loss	0.9900
2:223599296:CCT:C	acceptor_gain	0.9900
2:223599297:C:CC	acceptor_gain	0.9900
2:223599298:T:C	acceptor_gain	0.9900
2:223602283:ACCT:A	donor_gain	0.9900
2:223602284:CCTC:C	donor_gain	0.9900
2:223602284:CCTCT:C	donor_gain	0.9900
2:223599297:C:T	acceptor_gain	0.9800
2:223602283:AC:A	donor_gain	0.9800
2:223602284:CC:C	donor_gain	0.9800
2:223602286:T:TA	donor_gain	0.9800
2:223599292:ATTTC:A	acceptor_gain	0.9700
2:223599298:T:TC	acceptor_gain	0.9700
2:223600042:CGTG:C	acceptor_gain	0.9700
2:223599294:TTC:T	acceptor_gain	0.9600
2:223599305:A:C	acceptor_gain	0.9600
2:223599295:TC:T	acceptor_gain	0.9500
2:223602140:A:AC	donor_gain	0.9500
2:223602141:C:CC	donor_gain	0.9500
2:223600012:C:CC	acceptor_gain	0.9400
2:223599213:C:CT	acceptor_gain	0.9200
2:223599213:C:T	acceptor_gain	0.9200

AlphaMissense

4134 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:223598685:A:G	S200P	0.998
2:223598690:A:G	L198S	0.998
2:223598697:C:G	A196P	0.998
2:223598699:A:G	L195P	0.998
2:223598681:A:T	V201D	0.996
2:223598696:G:T	A196D	0.996
2:223598669:A:G	L205P	0.994
2:223598231:A:G	L351P	0.993
2:223598533:C:A	W250C	0.993
2:223598533:C:G	W250C	0.993
2:223598678:A:G	F202S	0.993
2:223598699:A:T	L195H	0.993
2:223598742:G:T	R181S	0.993
2:223599089:A:G	L65P	0.992
2:223598743:T:A	K180N	0.991
2:223598743:T:G	K180N	0.991
2:223598535:A:G	W250R	0.990
2:223598535:A:T	W250R	0.990
2:223598704:T:A	Q193H	0.990
2:223598704:T:G	Q193H	0.990
2:223598934:C:G	A117P	0.990
2:223598189:A:G	L365S	0.989
2:223598677:G:C	F202L	0.989
2:223598677:G:T	F202L	0.989
2:223598678:A:C	F202C	0.989
2:223598679:A:G	F202L	0.989
2:223599111:C:G	A58P	0.985
2:223598714:T:C	Y190C	0.984
2:223598732:T:A	E184V	0.984
2:223598741:C:G	R181P	0.984

dbSNP variants (sampled 300 via entrez): RS1000064865 (2:223603204 A>T), RS1000188768 (2:223600246 G>T), RS1000998095 (2:223601899 A>C,G), RS1001743708 (2:223599891 C>G), RS1002207653 (2:223597802 T>C), RS1002307513 (2:223603030 G>A), RS1003367778 (2:223597849 A>C,T), RS1003472685 (2:223599630 T>C), RS1003852381 (2:223599296 C>A,T), RS1004702550 (2:223604297 G>A,C), RS1005092013 (2:223604256 ACT>A), RS1005112853 (2:223597007 T>A), RS1005777171 (2:223600503 A>C), RS1005830771 (2:223601367 C>A), RS1006783707 (2:223602576 G>A,T)

Disease associations

OMIM: gene MIM:118930 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST000575_1	Osteoporosis-related phenotypes	4.000000e-06
GCST001325_2	Response to hepatitis C treatment	3.000000e-06
GCST002794_14	Airway wall thickness	5.000000e-08
GCST002794_5	Airway wall thickness	9.000000e-06
GCST002794_8	Airway wall thickness	2.000000e-06
GCST003542_31	Night sleep phenotypes	5.000000e-06
GCST006032_4	Sodium levels	4.000000e-13
GCST006186_4	Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)	4.000000e-06
GCST006193_92	Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	1.000000e-07
GCST006195_83	Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	2.000000e-09
GCST006427_35	Depression in smokers	5.000000e-06
GCST011685_1	Fasting plasma glucose	7.000000e-07
GCST012303_6	Recurrent major depressive disorder x sex interaction	6.000000e-06

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0006898	airway wall thickness measurement
EFO:0009282	sodium measurement
EFO:0006335	systolic blood pressure
EFO:0006527	smoking status measurement
EFO:0006336	diastolic blood pressure
EFO:0008343	sex interaction measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	3
bisphenol A	increases expression, increases methylation	2
Cisplatin	decreases expression, increases reaction, affects expression	2
Fluorouracil	decreases expression, increases expression, affects response to substance	2
Nickel	increases expression	2
propionaldehyde	increases expression	1
2,5,2’,5’-tetrachlorobiphenyl	increases expression	1
trichostatin A	increases expression	1
methylparaben	decreases expression	1
sodium arsenite	increases expression	1
zinc chromate	increases abundance, increases expression	1
rutecarpine	decreases expression	1
nickel sulfate	increases expression	1
chromium hexavalent ion	increases abundance, increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	decreases expression, increases reaction	1
incobotulinumtoxinA	increases expression	1
(+)-JQ1 compound	decreases expression	1
Wortmannin	decreases activity	1
Temozolomide	increases expression	1
Decitabine	affects expression	1
Arsenic Trioxide	decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Cadmium	increases expression	1
Doxorubicin	decreases expression	1
Endosulfan	increases expression	1
Lead	affects expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1UA	Abcam U-87MG SCG2 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.